AbbVie Inc. (ABBV)
| Market Cap | 334.31B |
| Revenue (ttm) | 57.37B |
| Net Income (ttm) | 4.16B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.34 |
| PE Ratio | 80.88 |
| Forward PE | 15.15 |
| Dividend | $6.56 (3.47%) |
| Ex-Dividend Date | Jul 15, 2025 |
| Volume | 5,244,750 |
| Open | 191.51 |
| Previous Close | 191.40 |
| Day's Range | 188.57 - 192.34 |
| 52-Week Range | 163.81 - 218.66 |
| Beta | 0.48 |
| Analysts | Buy |
| Price Target | 213.14 (+12.62%) |
| Earnings Date | Jul 31, 2025 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $213.14, which is an increase of 12.62% from the latest price.
News
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on high...
Why AbbVie Is a Strong Buy for Long-Term Investors in 2025
AbbVie Inc. (ABBV) has emerged as a strong performer in financial and technical terms, attracting investor attention due to its long-term growth potential. With consistent revenue generation and expan...
My Top 2 Earnings Picks For This Earnings Season
This morning, I woke up to the sound of pounding rain on the roof of my bus and a generator that made me decide to take the day off. Add in some flash flooding, a Wi-Fi signal riding on Starlink, and ...
A Sweet Spot Between Yield And Growth: The Best Balanced Dividend Growers For 2025
This isn't a buy list. It's a shortlist to help you speed up your research. We've included both U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull a...
Glenmark Pharma jumps on unit's cancer licensing deal with AbbVie
Shares of Glenmark Pharmaceuticals jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie for its cancer treatment.
Why Is AbbVie Stock Trading Higher On Thursday?
IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI's lead investiga...
Final Trades: Abbvie, Boeing, Oracle and Joby Aviation
The Investment Committee give you their top stocks to watch for the second half.
India's Glenmark Pharma unit, Abbvie sign exclusive licensing pact
India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have signed an exclusive global licensing agreement for IGI's cancer treatment, ISB 2...
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NORTH CHICAGO, Ill. and NEW YORK , July 10, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and ...
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying h...
2 ETFs To Prepare You For A Potential Recession
I see a 50-60% chance of a recession in the next 12–24 months, so portfolio preparation is essential. I recommend the iShares Gold Trust Micro as a low-cost gold ETF that has outperformed during recen...
AbbVie Stock At $190: Premium Pricing For A Transformation Story
AbbVie (NASDAQ:ABBV) has distinguished itself as one of the top performers in the healthcare sector this year, with its stock rising by 6% while the broader S&P 500 healthcare index fell by 1%. This o...
AbbVie to buy Capstan Therapeutics for up to $2.1 billion
AbbVie said on Monday it will acquire Capstan Therapeutics in a deal worth up to $2.1 billion, adding experimental treatments for autoimmune diseases to its portfolio.
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is ...
U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
SKINVIVE by JUVÉDERM® is currently approved in the U.S. as the first and only hyaluronic acid microdroplet injectable indicated to improve cheek skin smoothness. If approved, SKINVIVE by JUVÉDERM® wi...
AbbVie to Host Second-Quarter 2025 Earnings Conference Call
NORTH CHICAGO, Ill. , June 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens.
This Changes Everything: One Of The Most Important Shifts For Dividend Investors
Inflation isn't just back, it's becoming policy. From skewed CPI data to deficit-driven dollar moves, we're entering a new and lasting macro era. The U.S. may now prefer higher inflation to fix its ba...
Best Dividend Aristocrats For July 2025
Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising pa...
Elahere Market Opportunities and Strategies to 2034: Abbvie Secures European Approval for Elahere in Platinum-Resistant Ovarian Cancer
The global elahere market is set for rapid growth, projected to surge to $6.07 billion by 2034 at a CAGR of 28.68%. Key growth drivers include rising ovarian cancer prevalence, healthcare access in em...
My Dividend Stock Portfolio: New May Dividend Record - 100 Holdings With 15 Buys
Markets remained volatile in May 2025 amid ongoing trade tensions and mixed signals from Washington and Wall Street. While U.S.-China talks quietly resumed, tariffs persisted and business sentiment st...
2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'
Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. I highlight two such names that are undervalued compared to historical norms while paying strong and well-covered di...
3 dividend stocks investors can look for stability as Iran attacks US base in Qatar
US stocks could see pressure this week after Iran struck US bases in Qatar in retaliation for President Trump's airstrike on Tehran's nuclear facilities. Amidst the geopolitical backdrop that seems to...
I'm Buying Dividend Giants At Huge Discounts
Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth o...
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill. , June 20, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.